ESTRO 2024 - Abstract Book

S1030

Clinical - Gynaecology

ESTRO 2024

LACC patients from 2007-2021 (ESTHER study) received concurrent chemoradiation (CRT) with Cisplatin and BRT boost. Pre-treatment factors and SUV-max were analyzed for their impact on local control (LC), distant metastasis free survival (DMFS), disease-free survival (DFS), and overall survival (OS) using univariate and multivariate analyses.

Results:

173 patients, median 36-month follow-up (range: 3-151 months), were included. Older age was related to lower DMFS (univariate p=0.049, multivariate p=0.002) and OS (univariate p=0.003, multivariate p<0.001). Higher Hb levels (≥12 g/dL) correlated with improved LC (univariate p<0.001, multivariate p=0.002), DFS (only univariate p=0.007), and OS (univariate p=0.040, multivariate p=0.023). FIGO stage III-IV correlated with worse LC (p=0.005), DMFS (p=0.021), DFS (p=0.003), and OS (p=0.032) compared to FIGO stage I-II in univariate analysis. Multivariate analysis confirmed negative correlations with DMFS (p=0.002), DFS (p<0.001), and OS (p=0.003). Total CRT plus BRT dose correlated with improved OS (univariate p=0.012, multivariate p=0.038). No significant SUV-max correlation with outcomes was observed.

Conclusion: